Research Analysts Set Expectations for Illumina Q1 Earnings

Illumina, Inc. (NASDAQ:ILMN) – Leerink Partnrs cut their Q1 2026 EPS estimates for shares of Illumina in a research report issued on Monday, November 17th. Leerink Partnrs analyst P. Souda now forecasts that the life sciences company will post earnings of $0.98 per share for the quarter, down from their previous estimate of $1.13. The consensus estimate for Illumina’s current full-year earnings is $4.51 per share. Leerink Partnrs also issued estimates for Illumina’s Q4 2026 earnings at $1.43 EPS, FY2026 earnings at $5.08 EPS and FY2027 earnings at $6.17 EPS.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.16 by $0.18. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the business earned $1.14 EPS. Illumina’s revenue for the quarter was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS.

Several other research firms have also commented on ILMN. JPMorgan Chase & Co. lifted their price target on Illumina from $100.00 to $105.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Wall Street Zen upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (d+)” rating on shares of Illumina in a research note on Wednesday, October 8th. Evercore ISI increased their target price on shares of Illumina from $132.00 to $142.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. Finally, UBS Group boosted their price target on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Five analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $115.00.

Illumina Stock Up 1.6%

ILMN opened at $121.97 on Wednesday. Illumina has a one year low of $68.70 and a one year high of $153.06. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a market capitalization of $18.64 billion, a P/E ratio of 15.44, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The business’s 50-day simple moving average is $103.75 and its 200-day simple moving average is $96.73.

Insider Buying and Selling

In other Illumina news, Director Scott Gottlieb acquired 500 shares of the stock in a transaction on Monday, November 3rd. The shares were bought at an average price of $122.13 per share, with a total value of $61,065.00. Following the acquisition, the director owned 12,523 shares of the company’s stock, valued at $1,529,433.99. This trade represents a 4.16% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.17% of the stock is currently owned by insiders.

Institutional Trading of Illumina

A number of institutional investors have recently modified their holdings of the business. Assetmark Inc. boosted its stake in Illumina by 10.2% during the 3rd quarter. Assetmark Inc. now owns 1,039 shares of the life sciences company’s stock worth $99,000 after acquiring an additional 96 shares during the last quarter. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Illumina by 0.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 12,074 shares of the life sciences company’s stock valued at $1,152,000 after buying an additional 99 shares during the period. Versant Capital Management Inc increased its position in shares of Illumina by 8.9% in the 3rd quarter. Versant Capital Management Inc now owns 1,364 shares of the life sciences company’s stock valued at $130,000 after buying an additional 111 shares in the last quarter. Parkside Financial Bank & Trust raised its stake in Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares during the period. Finally, Archer Investment Corp lifted its holdings in Illumina by 12.9% during the third quarter. Archer Investment Corp now owns 1,073 shares of the life sciences company’s stock worth $102,000 after acquiring an additional 123 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.